To report the therapeutic value of sulodexide monotherapy in the management of patients with chronic subjective idiopathic tinnitus.
Study Design
Randomized double-blinded controlled trial.
Setting
Single tertiary care institution.
Subjects and Methods
Observations from 124 patients who received either sulodexide or placebo were collected from the patients’ medical records. Computer-generated tables were used to allocate treatments. Patients took 1 tablet of the drug or placebo each morning and evening for 40 consecutive days. The response was assessed by the Tinnitus Handicap Inventory and the Mini-Tinnitus Questionnaire.
Results
Between 2014 and 2017, 124 patients were divided into 2 treatment arms. The sulodexide group encompassed 63 patients, whereas the placebo arm contained 61 patients. Tinnitus Handicap Inventory and Mini-Tinnitus Questionnaire scores were more decreased in the sulodexide arm compared to the placebo group (P = .03 and P < .01, respectively).
VioMMHolmeRH. Hearing loss and tinnitus: 250 million people and a US$10 billion potential market. Drug Discov Today. 2005;10:1263-1265.
2.
MrenaRYlikoskiMMakitieAPirvolaUYlikoskiJ. Occupational noise-induced hearing loss reports and tinnitus in Finland. Acta Otolaryngol. 2007;127:729-735.
3.
MichikawaTNishiwakiYKikuchiYet al. Prevalence and factors associated with tinnitus: a community-based study of Japanese elders. J Epidemiol. 2010;20:271-276.
4.
DobieRA. Depression and tinnitus. Otolaryngol Clin North Am. 2003;36:383-388.
5.
KaltenbachJA. The dorsal cochlear nucleus as a participant in the auditory, attentional and emotional components of tinnitus. Hear Res. 2006;216-217:224-234.
6.
MeyerMLangguthBKleinjungTMollerAR. Plasticity of neural systems in tinnitus. Neural Plast. 2014;2014:968029.
7.
MiyamotoRTBicheyBG. Cochlear implantation for tinnitus suppression. Otolaryngol Clin North Am. 2003;36:345-352.
8.
BaguleyDMAtlasMD. Cochlear implants and tinnitus. Prog Brain Res. 2007;166:347-355.
9.
ShulmanAGoldsteinB. Intratympanic drug therapy with steroids for tinnitus control: a preliminary report. Int Tinnitus J. 2000;6:10-20.
10.
HofferMEWesterDKopkeRDWeisskopfPGottshallK. Transtympanic management of tinnitus. Otolaryngol Clin North Am. 2003;36:353-358.
11.
VernonJAMeikleMB. Masking devices and alprazolam treatment for tinnitus. Otolaryngol Clin North Am. 2003;36:307-320, vii.
12.
JastreboffMM. Sound therapies for tinnitus management. Prog Brain Res. 2007;166:435-440.
JastreboffPJJastreboffMM. Tinnitus retraining therapy: a different view on tinnitus. ORL J Otorhinolaryngol Relat Spec. 2006;68:23-29, discussion 29-30.
15.
HesserHWeiseCWestinVZAnderssonG. A systematic review and meta-analysis of randomized controlled trials of cognitive-behavioral therapy for tinnitus distress. Clin Psychol Rev. 2011;31:545-553.
LauverDALucchesiBR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006;24:214-226.
18.
LiawPCBeckerDLStaffordARFredenburghJCWeitzJI. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem. 2001;276:20959-20965.
19.
GambaroGKinalskaIOksaAet al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615-1625.
20.
AchourAKacemMDibejKSkhiriHBouraouiSEl MayM. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005;18:568-574.
21.
CirujedaJLGranadoPC. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006;57:53-64.
22.
ErrichiBMCesaroneMRBelcaroGet al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology. 2004;55:243-249.
23.
ElleuchNZidiHBellamineZet al. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016;33:1536-1549.
24.
SavianoMMaletiOLiguoriL. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin. 1993;13:96-108.
25.
NeriGDe StefanoABaffaCet al. Treatment of central and sensorineural tinnitus with orally administered melatonin and sulodexide: personal experience from a randomized controlled study. Acta Otorhinolaryngol Ital. 2009;29:86-91.
26.
FerrariGAgneseACavalleroAet al. Medical and surgical treatments for tinnitus: the efficacy of combined treatment with sulodexide and melatonin. J Neurosurg Sci. 2015;59:1-9.
27.
El BeainoMEterE. Arabic validation of the Tinnitus Handicap Inventory and the Mini-Tinnitus Questionnaire on 100 adult patients. Clin Otolaryngol. 2018;43:377-382.
28.
NewmanCWJacobsonGPSpitzerJB. Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg. 1996;122:143-148.
29.
HillerWGoebelG. Rapid assessment of tinnitus-related psychological distress using the Mini-TQ. Int J Audiol. 2004;43:600-604.
30.
HoareDJKowalkowskiVLHallDA. Effects of frequency discrimination training on tinnitus: results from two randomised controlled trials. J Assoc Res Otolaryngol. 2012;13:543-559.
31.
JalaliMMKoushaANaghaviSESoleimaniRBananR. The effects of alprazolam on tinnitus: a cross-over randomized clinical trial. Med Sci Monit. 2009;15:PI55-PI60.
32.
HoareDJHallDA. Clinical guidelines and practice: a commentary on the complexity of tinnitus management. Eval Health Prof. 2011;34:413-420.
33.
HenryJADennisKCSchechterMA. General review of tinnitus: prevalence, mechanisms, effects, and management. J Speech Lang Hear Res. 2005;48:1204-1235.
34.
TylerRSNobleWCoelhoC. Considerations for the design of clinical trials for tinnitus. Acta Otolaryngol Suppl. 2006;(556):44-49.
35.
MannelloFMeddaVLigiDRaffettoJD. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11:354-365.
36.
LiuYNZhouJLiTet al. Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating Klotho expression at an early stage of diabetic kidney disease. J Diabetes Res. 2017;2017:4989847.
